osmium-tellurium nanorods

Osmium-tellurium nanorods (OsTeNRs) are synthesized nanomaterial constructs consisting of osmium and tellurium in a nanorod morphology. They are developed as nanozymes for combinatorial cancer therapy, notably for hepatocellular carcinoma (HCC). OsTeNRs exhibit multi-modal therapeutic activities, including nanozymatic (enzyme-mimetic) activity, photothermal conversion, photocatalytic (photodynamic) activity, and are used in combination with chemotherapy (e.g., regorafenib) and immunotherapy for pentamodal combinatorial therapy[5]. In vitro and in vivo studies demonstrated that OsTeNRs can alleviate tumor hypoxia by generating oxygen, enable sustained drug release (reducing unintended organ accumulation and bone marrow toxicity), and demonstrate superior photothermal conversion and photocatalytic capabilities[5][6]. The nanorods are synthesized by solvothermal galvanic replacement using tellurium nanotemplates[2][5][6]. Their primary indication under investigation is advanced HCC, with potential applications in other cancers or biomedical fields not yet specified.

Other names

osmium-tellurium nanozymesOs-Te nanorods